Photocure appoints Genotests as exclusive partner for Hexvix in Chile

Bladder cancer ranks as the sixth most common cancer worldwide with 1 650 000
prevalent cases (5 year prevalence rate), 550 000 new cases and almost 200 000
deaths annually in 2018.

OSLO: Photocure ASA announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix in Chile.

“We are proud to take our first step into the South American continent and make Hexvix accessible to Chilean bladder cancer patients. Chile is a stable, well regulated market with a strong economy, and Genotests is well positioned to leverage their network of urologists and uro-oncologists both in the private and public hospitals”, says Dan Schneider, President and CEO of Photocure.

Photocure has appointed Genotests, a privately held company founded in 2014 specializing in genetic tests for cancer targeting cancer specialists, as the exclusive distributor of Hexvix in Chile. Under the terms of the agreement, Genotests will fund all costs to secure regulatory approval and the launch and commercialization of Hexvix in Chile. Photocure will manufacture the product and  support Genotests with the regulatory file, training and promotional materials.

There are approximately 1500 new bladder cancer cases annually in Chile, an estimated 5000 TURBT procedures and nearly 3000 surveillance cystoscopies.

“I am delighted to get the opportunity to bring Hexvix to Chile. It is a fantastic product that the urology community has been waiting for, especially after the successful demo done in collaboration with Karl Storz at the Chilean Urology Conference. After following Photocure and Hexvix/Cysview for years I know it is a complex sell, and we are well prepared with an established relationship with the leading cystoscopy equipment supplier. We’ll initiate the regulatory submission process immediately and look very much forward to work with the Photocure team”, says Oscar Varas, founder and owner of Genotests.

Photocure , the Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO).

Genotests is a medical company in-licensing and commercializing innovative cancer diagnostics test and treatments for health care providers and their patients in the Latin America & Caribbean countries, with special emphasis in the field of uro-oncology.

Leave a Reply

Your email address will not be published. Required fields are marked *